India  

Oxford–AstraZeneca COVID-19 vaccine

Viral vector vaccine for prevention of COVID-19 by Oxford University and AstraZeneca

Oxford–AstraZeneca COVID-19 vaccine    ▸ Facts   ▸ Comments   ▸ News   ▸ Videos   

Oxford–AstraZeneca COVID-19 vaccine: Viral vector vaccine for prevention of COVID-19 by Oxford University and AstraZeneca
The Oxford–AstraZeneca COVID‑19 vaccine, sold under the brand names Covishield and Vaxzevria among others, is a viral vector vaccine for the prevention of COVID-19. It was developed in the United Kingdom by Oxford University and British-Swedish company AstraZeneca, using as a vector the modified chimpanzee adenovirus ChAdOx1. The vaccine is given by intramuscular injection. Studies carried out in 2020 showed that the efficacy of the vaccine is 76.0% at preventing symptomatic COVID-19 beginning at 22 days following the first dose and 81.3% after the second dose. A study in Scotland found that, for symptomatic COVID-19 infection after the second dose, the vaccine is 81% effective against the Alpha variant and 61% against the Delta variant.

0
shares
ShareTweetSavePostSend
 

You Might Like


1 in 3 Covaxin recipients hit by adverse events: Study

Nearly one-third of Covaxin recipients experienced adverse events of special interest within a year, including respiratory, skin, and musculoskeletal issues. The study also highlighted menstrual..
IndiaTimes - Published

Stopped producing Covishield in Dec 2021: SII after AstraZeneca recall

UK-based drug major AstraZeneca's decision to withdraw its Covid-19 vaccine globally, days after admitting to side effects, prompted Serum Institute of India to disclose that it had stopped..
IndiaTimes - Published

'Manufacturing of Covishield ceased two years back due to poor demand'


IndiaTimes - Published

SII stopped manufacturing Covishield since December 2021, says 'disclosed side effects details in packaging insert'

SII stopped Covishield extra doses due to lawsuit, disclosed rare Thrombosis. Advocates govt collaboration. AstraZeneca withdraws Vaxzevria marketing authorisations globally. European Medicines Agency..
IndiaTimes - Published

55% Covidshield recipients had mild side effects: AMCH study


IndiaTimes - Published

AstraZeneca admits Covishield vaccines raises rare side-effects risk. How worried should you be?

In India, almost 90% of people who received Covid vaccine, received the AstraZeneca vaccine which in India is called Covishield.
DNA - Published

Take down defamatory posts on Covishield: Bombay high court


IndiaTimes - Published

Content posted against Serum Institute of India, its Covishield vaccine prima facie defamatory: Bombay HC

The Bombay high court on Monday said content posted by two individuals and their organisations against vaccine manufacturing major Serum Institute of India (SII) was "prima facie defamatory" and..
IndiaTimes - Published

SII to restart vaccine production amid surge in Covid cases

Serum Institute of India CEO Adar Poonawalla told TOI on Wednesday that the company has resumed production of its Covid-19 vaccine, Covishield, in response to the increasing number of SARS-CoV-2 virus..
IndiaTimes - Published

Serum Institute of India restarts manufacturing of Covid-19 vaccine Covishield

Serum Institute of India CEO Adar Poonawalla on Wednesday said the company has restarted manufacturing of Covid-19 vaccine Covishield amid rising numbers of cases of the virus infection. He said the..
IndiaTimes - Published

Covid jab Covovax as heterologous booster to be available on CoWIN soon; to cost Rs 225 per dose

Covovax can be administered to those who have already vaccinated with Covishield or Covaxin. The Drugs Controller General of India (DCGI) on January 16 had approved the market authorisation for Covovax..
IndiaTimes - Published

Drug panel favours nod for Covovax as Covid booster

An expert panel of the central drug regulatory authority has recommended market authorisation for Serum Institute of India’s Covid vaccine, Covovax, as a heterologous booster dose for adults who have..
IndiaTimes - Published

Covovax may get approval as heterologous booster

The government may decide on allowing Serum Institute of India’s (SII) Covovax as a heterologous booster dose, meaning it can be used for people who have taken either Covishield or Covaxin for..
IndiaTimes - Published

Covid-19: Covovax to get approval as booster in 10-15 days, says SII CEO Adar Poonawalla

Serum Institute of India chief executive officer Adar Poonawalla on Sunday said its Covovax vaccine will get approval as a booster in the next 10 to 15 days, adding it works very well against the..
IndiaTimes - Published

Serum Institute to provide 2 crore Covishield doses to central govt free of cost


IndiaTimes - Published

No shortage of Covishield, says Poonawalla


IndiaTimes - Published

Bill Gates, SII get Bombay High Court notice as petitioner claims Covishield killed his daughter

The petitioner blamed the authorities for creating false narratives about the Covishield vaccine. He has sought compensation of Rs 1,000 crore.
DNA - Published

Govt: Sputnik V recipients can take Covishield, Covaxin booster


IndiaTimes - Published

Corbevax gets nod as booster after Covishield, Covaxin shots


IndiaTimes - Published

India to start Covid mix-and-match booster vaccines on Friday

India said on Wednesday that Biological E's Covid-19 vaccine Corbevax can be administered as a booster dose in people who have taken the country's other two main shots, Covaxin and AstraZeneca's..
IndiaTimes - Published

Biological E's Corbevax approved as booster dose for adults vaccinated with Covaxin, Covishield

This is for the first time that a booster dose that is different from the one used for primary vaccination against Covid has been allowed in India.
DNA - Published Also reported by •IndiaTimes

Govt nod for Corbevax as booster for adults vaccinated with Covishield, Covaxin soon


IndiaTimes - Published

Health ministry seeks 5 crore free Covishield doses from GAVI under COVAX

The Union health ministry has asked global vaccine alliance GAVI to supply 5 crore of the allocated 10 crore doses of Covishield to India under the COVAX facility free of cost, official sources said on..
IndiaTimes - Published

Corbevax being considered as booster dose for Covishield, Covaxin jabbed people

NTAGI is considering using Corbevax as a booster vaccination against Covid-19.
DNA - Published

NTAGI to discuss allowing Corbevax as booster shot for Covishield, Covaxin recipients: Sources

Allowing Biological E's Corbevax as a booster for those fully vaccinated against Covid-19 with either Covishield or Covaxin and reducing the gap between the second dose and the precaution dose of the..
IndiaTimes - Published

Corbevax maker seeks emergency use approval as booster jab for adults vaccinated with Covishield, Covaxin

There were 416 patients aged 18 to 80 who got two doses of Covaxin or Covishield, the last one six months before the Corbevax booster.
DNA - Published

Breakthrough Delta infection, reinfection with Omicron in person vaccinated with Covishield

The patient received the first dose of Covishield vaccine on January 31, 2021, and the second dose on March 3, 2021.
DNA - Published

Covid Update: Get Covaxin, Covishield at Rs 225

Price slash of Covaxin and Covishield was announced after the government allowed all above 18 years of age can get booster dose from April 10.
DNA - Published

Bharat Biotech, SII slash prices of Covaxin, Covishield booster dose to Rs 225 per shot


IndiaTimes - Published

Covishield, Covaxin prices slashed ahead of booster drive expansion

Serum Institute of India has reduced the price of its Covishield vaccine from Rs 600 to Rs 225 per dose for private hospitals, the vaccine maker announced on Saturday. Bharat Biotech also slashed the..
IndiaTimes - Published

Serum Institute of India prices Covishield booster dose at Rs 600

SII CEO Adar Poonawalla also welcomed the government's move to allow precautionary doses of the vaccine to all aged above 18 years.
DNA - Published

Serum Institute's Covishield precaution dose priced at Rs 600 per shot

Vaccine maker Serum Institute of India (SII) on Friday said the precaution dose of its Covishield vaccine against Covid-19 will be priced at Rs 600 per shot for eligible individuals.
IndiaTimes - Published

ICMR study shows increase in antibodies after receiving Covaxin booster dose, says MoS Health

International data available on booster doses of AstraZeneca & Covishield suggests 3 to 4 fold increase in antibody levels after their administration.
DNA - Published

As cases rise elsewhere, govt set to cut Covishield shots gap

The government’s top vaccination advisory panel, National Technical Advisory Group on Immunisation (NTAGI), has recommended reducing the interval between the two primary doses of Covishield to 8-16..
IndiaTimes - Published

Gap between first and second Covishield vaccine doses reduced to 8-16 weeks

Presently, the second dose of Covishield is given between 12-16 weeks after the first dose under the National COVID-19 Vaccination Strategy.
DNA - Published

Second Covishield dose can be given between 8-16 weeks after first dose, says NTAGI reducing gap


IndiaTimes - Published

Mixing Covishield & Covaxin gives better immunity: ICMR


IndiaTimes - Published

SII urges Mandaviya to reduce gap between 2nd, precaution dose of Covishield from 9 to 3 months


IndiaTimes - Published

Media reports claiming 50 lakh unused Covishield doses may go waste by month end 'misleading': Govt

The Union health ministry on Thursday refuted as “misleading” media reports which claimed that 50 lakh unused Covishield doses may go waste by the end of this month. It said the Centre had..
IndiaTimes - Published

Serum Institute has applied for full market authorisation of Covishield: CEO Adar Poonawala

Serum Institute has applied to the Indian health ministry and Central Drugs Standard Control Organisation (CDSCO) for full market authorisation for its Covishield vaccine, company's CEO Adar Poonawalla..
IndiaTimes - Published

India-Bangladesh bonhomie scaled new heights as 2021 marked 50 years of ties

The year began on a promising note as Bangladesh PM Sheikh Hasina thanked her Indian counterpart Narendra Modi for sending over two million doses of AstraZeneca-Oxford University vaccine Covishield, as..
IndiaTimes - Published

Covishield cover high 7 months after 2 doses, 90% antibody prevalence seen: Study


IndiaTimes - Published

Covishield production capacity 250-275 million doses a month, Covaxin 50-60 million: Govt


IndiaTimes - Published

ICMR focus on two-dose vax, is fine with current Covishield gap


IndiaTimes - Published

Government panel rejects SII's plea to administer a third dose of Covishield vaccine

SII sought approval to administer the third dose on the basis of adequate stock of Covishield and rising demand for boosters amid emergence of Omicron
DNA - Published

CDSCO panel seeks local clinical trial data from SII for approval of Covishield as booster dose


IndiaTimes - Published

Subject Expert Committee to meet on Dec 10 to discuss approval for Covishield booster dose


IndiaTimes - Published

Not enough orders, may cut Covishield output by 50%: SII

With not enough orders for Covishield from the Centre, Serum Institute of India CEO Adar Poonawalla on Tuesday said the company is looking at slashing monthly production of vaccines by at least 50% %...
IndiaTimes - Published

Covid-19: A wide range of vaccines act as booster to AstraZeneca, Pfizer shots, says study

Up to six different Covid-19 boosters were found to be safe, and provoked strong immune responses in people who have previously received a two-dose course of the Oxford-AstraZeneca-developed..
IndiaTimes - Published

As Omicron fear intensifies, Serum Institute of India seeks DCGI's approval for Covishield booster shot

Recently, Kerala, Rajasthan, Karnataka, and Chhattisgarh have also urged the Centre to decide on allowing booster doses of the COVID-19 vaccine.
DNA - Published


 Page 1  〉